Wai BioLogics signs a joint research contract with Galax for AI-based drug development [Korean]
Wai BioLogics has signed a collaborative research agreement with Galax to develop AI-based cancer drugs. The partnership will focus on antibody-based immuno-oncology therapies, combining Wai BioLogics’ antibody platform with Galax’s AI drug design technology to create next-generation treatments for various diseases.